These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 26759984)

  • 1. Linking Costs and Survival in the Treatment of Older Adults With Chronic Myeloid Leukemia: An Analysis of SEER-Medicare Data From 1995 to 2007.
    Lin PJ; Winn AN; Parsons SK; Neumann PJ; Weiss ES; Cohen JT
    Med Care; 2016 Apr; 54(4):380-5. PubMed ID: 26759984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The costs of treating and not treating patients with chronic myeloid leukemia with tyrosine kinase inhibitors among Medicare patients in the United States.
    Seymour EK; Ruterbusch JJ; Winn AN; George JA; Beebe-Dimmer JL; Schiffer CA
    Cancer; 2021 Jan; 127(1):93-102. PubMed ID: 33119175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment patterns, outcomes and costs among elderly patients with chronic myeloid leukaemia: a population-based analysis.
    Menzin J; Lang K; Earle CC; Glendenning A
    Drugs Aging; 2004; 21(11):737-46. PubMed ID: 15323579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in all-cause mortality among patients with chronic myeloid leukemia: a Surveillance, Epidemiology, and End Results database analysis.
    Brunner AM; Campigotto F; Sadrzadeh H; Drapkin BJ; Chen YB; Neuberg DS; Fathi AT
    Cancer; 2013 Jul; 119(14):2620-9. PubMed ID: 23625575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
    Reed SD; Anstrom KJ; Ludmer JA; Glendenning GA; Schulman KA
    Cancer; 2004 Dec; 101(11):2574-83. PubMed ID: 15493042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.
    Warren E; Ward S; Gordois A; Scuffham P
    Clin Ther; 2004 Nov; 26(11):1924-33. PubMed ID: 15639704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Chemotherapy for Breast Cancer and Age Effect in Older Women.
    Lairson DR; Parikh RC; Cormier JN; Chan W; Du XL
    Value Health; 2015 Dec; 18(8):1070-8. PubMed ID: 26686793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medicare and patient spending among beneficiaries diagnosed with chronic myelogenous leukemia.
    Kenzik KM; Bhatia R; Williams GR; Bhatia S
    Cancer; 2019 Aug; 125(15):2570-2578. PubMed ID: 30973642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib--a Swedish model application.
    Ghatnekar O; Hjalte F; Taylor M
    Acta Oncol; 2010 Aug; 49(6):851-8. PubMed ID: 20615173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mortality and Vascular Events Among Elderly Patients With Chronic Myeloid Leukemia: A Retrospective Analysis of Linked SEER-Medicare Data.
    Lang K; McGarry LJ; Huang H; Dorer D; Kaufman E; Knopf K
    Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):275-285.e1. PubMed ID: 27013180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of healthcare resource utilization and incremental economic burden of patients with chronic myeloid leukemia after disease progression to blast phase.
    Jabbour EJ; Lin J; Siegartel LR; Lingohr-Smith M; Menges B; Makenbaeva D
    J Med Econ; 2017 Sep; 20(9):1007-1012. PubMed ID: 28681664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia.
    Winn AN; Keating NL; Dusetzina SB
    J Clin Oncol; 2016 Dec; 34(36):4323-4328. PubMed ID: 27998234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of medical spending in the United States, 1960-2000.
    Cutler DM; Rosen AB; Vijan S
    N Engl J Med; 2006 Aug; 355(9):920-7. PubMed ID: 16943404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Anticancer Drugs Associated With Large Increases In Costs And Life Expectancy.
    Howard DH; Chernew ME; Abdelgawad T; Smith GL; Sollano J; Grabowski DC
    Health Aff (Millwood); 2016 Sep; 35(9):1581-7. PubMed ID: 27605636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness study comparing imatinib with interferon-alpha for patients with newly diagnosed chronic-phase (CP) chronic myeloid leukemia (CML) from the Chinese public health-care system perspective (CPHSP).
    Chen Z; Wang C; Xu X; Feng W
    Value Health; 2009; 12 Suppl 3():S85-8. PubMed ID: 20586990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic assessment of decision-analytic models for chronic myeloid leukemia.
    Rochau U; Schwarzer R; Jahn B; Sroczynski G; Kluibenschaedl M; Wolf D; Radich J; Brixner D; Gastl G; Siebert U
    Appl Health Econ Health Policy; 2014 Apr; 12(2):103-15. PubMed ID: 24385259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between insurance status at diagnosis and overall survival in chronic myeloid leukemia: A population-based study.
    Perry AM; Brunner AM; Zou T; McGregor KL; Amrein PC; Hobbs GS; Ballen KK; Neuberg DS; Fathi AT
    Cancer; 2017 Jul; 123(13):2561-2569. PubMed ID: 28464280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of new chemotherapeutic agents for metastatic colorectal cancer.
    Howard DH; Kauh J; Lipscomb J
    Arch Intern Med; 2010 Mar; 170(6):537-42. PubMed ID: 20233802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival trends in childhood chronic myeloid leukaemia in Southern-Eastern Europe and the United States of America.
    Karalexi MA; Baka M; Ryzhov A; Zborovskaya A; Dimitrova N; Zivkovic S; Eser S; Antunes L; Sekerija M; Zagar T; Bastos J; Demetriou A; Agius D; Florea M; Coza D; Polychronopoulou S; Stiakaki E; Moschovi M; Hatzipantelis E; Kourti M; Graphakos S; Pombo-de-Oliveira MS; Adami HO; Petridou ET
    Eur J Cancer; 2016 Nov; 67():183-190. PubMed ID: 27677054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disparities in chronic myeloid leukemia survival by age, gender, and ethnicity in pre- and post-imatinib eras in the US.
    Mandal R; Bolt DM; Shah BK
    Acta Oncol; 2013 May; 52(4):837-41. PubMed ID: 23181388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.